Literature DB >> 17374532

Effect of adenosine receptor subtypes stimulation on mixed lymphocyte reaction.

Hideo Kohka Takahashi1, Hiromi Iwagaki, Ryosuke Hamano, Toru Kanke, Keyue Liu, Hiroshi Sadamori, Takahito Yagi, Tadashi Yoshino, Toshiaki Sendo, Noriaki Tanaka, Masahiro Nishibori.   

Abstract

The cell-to-cell interaction through binding of intercellular adhesion molecule (ICAM)-1 on monocytes to their ligands lymphocyte function-associated antigen (LFA)-1 on T-cells plays important roles in cytokine production and T-cell proliferation. Interleukin (IL)-18, which plasma levels are elevated in patients during acute rejection following organ transplantation, induces the expression of ICAM-1 on monocytes, production of interferon (IFN)-gamma and IL-12 and lymphocyte proliferation during human mixed lymphocyte reaction. Activation of the adenosine A(2A) receptor on during reperfusion of various tissues has been found to markedly reduce ischemia-reperfusion injury. In the present study, we examined the effect of adenosine at increasing concentrations ranging from 0.1 to 100 microM on the IL-18-enhanced expression of ICAM-1, production of IFN-gamma and IL-12 and lymphocyte proliferation during human mixed lymphocyte reaction. Adenosine inhibited the IL-18-initiated immune responses. The IC(50) values of adenosine for inhibition of the IL-18-enhanced ICAM-1 expression, IFN-gamma production and lymphocyte proliferation were 20 microM, respectively. The actions of adenosine depended on the stimulation of adenosine A(2A) receptor. An inhibitor of protein kinase A (PKA) at 100 microM inhibited the actions of adenosine, suggesting that PKA might be involved in the actions of adenosine. On the other hand, the stimulation of adenosine A(1) and A(3) receptor blocked the actions of adenosine A(2A) receptor stimulation. These results suggest that adenosine inhibits the immune responses during mixed lymphocyte reaction via adenosine A(2A) receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17374532     DOI: 10.1016/j.ejphar.2007.02.005

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Regulation of lymphocyte function by adenosine.

Authors:  Joel Linden; Caglar Cekic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-07-05       Impact factor: 8.311

2.  Adenosine and stroke: maximizing the therapeutic potential of adenosine as a prophylactic and acute neuroprotectant.

Authors:  Rebecca L Williams-Karnesky; Mary P Stenzel-Poore
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

3.  A1 and A2A adenosine receptors play a protective role to reduce prevalence of autoimmunity following tissue damage.

Authors:  Reut Riff; Oshri Naamani; Julia Mazar; Yosef S Haviv; Cidio Chaimovitz; Amos Douvdevani
Journal:  Clin Exp Immunol       Date:  2021-06-02       Impact factor: 5.732

Review 4.  Purinergic signalling and immune cells.

Authors:  Geoffrey Burnstock; Jean-Marie Boeynaems
Journal:  Purinergic Signal       Date:  2014-10-29       Impact factor: 3.765

Review 5.  Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.

Authors:  Kevin Sek; Christina Mølck; Gregory D Stewart; Lev Kats; Phillip K Darcy; Paul A Beavis
Journal:  Int J Mol Sci       Date:  2018-12-02       Impact factor: 5.923

6.  CD39/CD73 Dysregulation of Adenosine Metabolism Increases Decidual Natural Killer Cell Cytotoxicity: Implications in Unexplained Recurrent Spontaneous Abortion.

Authors:  Jianan Zhu; Guangmin Song; Xiaobo Zhou; Ting-Li Han; Xinyang Yu; Hao Chen; Toby Mansell; Boris Novakovic; Philip N Baker; Richard D Cannon; Richard Saffery; Chang Chen; Hua Zhang
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

7.  Extracellular AMP Suppresses Endotoxemia-Induced Inflammation by Alleviating Neutrophil Activation.

Authors:  Ye Hua; Dadong Liu; Danyi Zhang; Xu Wang; Qing Wei; Weiting Qin
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.